Bile acid transporters and regulatory nuclear receptors in the liver and beyond

Hofmann, 2009, The enterohepatic circulation of bile acids in mammals: form and functions, Front Biosci, 14, 2584, 10.2741/3399 Hofmann, 2007, Biliary secretion and excretion in health and disease: current concepts, Ann Hepatol, 6, 15, 10.1016/S1665-2681(19)31949-0 Russell, 2009, Fifty years of advances in bile acid synthesis and metabolism, J Lipid Res, 50, S120, 10.1194/jlr.R800026-JLR200 Trauner, 2003, Bile salt transporters: molecular characterization, function, and regulation, Physiol Rev, 83, 633, 10.1152/physrev.00027.2002 Beuers, 1993, Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca2+ mechanisms defective in cholestasis, J Clin Invest, 92, 2984, 10.1172/JCI116921 Beuers, 1993, Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes, Gastroenterology, 104, 604, 10.1016/0016-5085(93)90433-D Beuers, 2001, Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver, Hepatology, 33, 1206, 10.1053/jhep.2001.24034 Schliess, 1997, Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver, Gastroenterology, 113, 1306, 10.1053/gast.1997.v113.pm9322526 Klaassen, 2010, Xenobiotic, bile acid, and cholesterol transporters: function and regulation, Pharmacol Rev, 62, 1, 10.1124/pr.109.002014 Maruyama, 2002, Identification of membrane-type receptor for bile acids (M-BAR), Biochem Biophys Res Commun, 298, 714, 10.1016/S0006-291X(02)02550-0 Rao, 2002, Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes, Hepatology, 35, 307, 10.1053/jhep.2002.31104 Kullak-Ublick, 2004, Enterohepatic bile salt transporters in normal physiology and liver disease, Gastroenterology, 126, 322, 10.1053/j.gastro.2003.06.005 Hagenbuch, 1994, Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter, J Clin Invest, 93, 1326, 10.1172/JCI117091 Kullak-Ublick, 1994, Functional characterization of the basolateral rat liver organic anion transporting polypeptide, Hepatology, 20, 411 Wagner, 2010, Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis, Semin Liver Dis, 30, 160, 10.1055/s-0030-1253225 Zollner, 2003, Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis, J Hepatol, 38, 717, 10.1016/S0168-8278(03)00096-5 Keitel, 2005, Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis, Hepatology, 41, 1160, 10.1002/hep.20682 Zollner, 2006, Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations, Mol Pharm, 3, 231, 10.1021/mp060010s Gerloff, 1998, The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver, J Biol Chem, 273, 10046, 10.1074/jbc.273.16.10046 Makishima, 1999, Identification of a nuclear receptor for bile acids, Science, 284, 1362, 10.1126/science.284.5418.1362 Stieger, 2011, The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation, Handb Exp Pharmacol, 205, 10.1007/978-3-642-14541-4_5 Lo Sasso, 2008, A translational view on the biliary lipid secretory network, Biochim Biophys Acta, 1781, 79, 10.1016/j.bbalip.2007.12.002 Cascorbi, 2011, P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations, Handb Exp Pharmacol, 261, 10.1007/978-3-642-14541-4_6 Meyer zu Schwabedissen, 2011, In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2), Handb Exp Pharmacol, 2, 325, 10.1007/978-3-642-14541-4_9 Dawson, 2009, Bile acid transporters, J Lipid Res, 50, 2340, 10.1194/jlr.R900012-JLR200 Hofmann, 2009, Bile acids: trying to understand their chemistry and biology with the hope of helping patients, Hepatology, 49, 1403, 10.1002/hep.22789 Halilbasic, 2009, Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice, Hepatology, 49, 1972, 10.1002/hep.22891 Claudel, 2011, Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease, Biochim Biophys Acta, 1812, 867, 10.1016/j.bbadis.2010.12.021 Shneider, 2001, Intestinal bile acid transport: biology, physiology, and pathophysiology, J Pediatr Gastroenterol Nutr, 32, 407, 10.1097/00005176-200104000-00002 Dawson, 2003, Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice, J Biol Chem, 278, 33920, 10.1074/jbc.M306370200 Inagaki, 2005, Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis, Cell Metab, 2, 217, 10.1016/j.cmet.2005.09.001 Choi, 2006, Identification of a hormonal basis for gallbladder filling, Nat Med, 12, 1253, 10.1038/nm1501 Sinha, 2008, Beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes, Am J Physiol Gastrointest Liver Physiol, 295, G996, 10.1152/ajpgi.90343.2008 Schaap, 2009, High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis, Hepatology, 49, 1228, 10.1002/hep.22771 Kir, 2011, FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis, Science, 331, 1621, 10.1126/science.1198363 Zweers, 2012, The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract, Hepatology, 55, 575, 10.1002/hep.24702 Thomas, 2009, TGR5-mediated bile acid sensing controls glucose homeostasis, Cell Metab, 10, 167, 10.1016/j.cmet.2009.08.001 Trauner, 1998, Molecular pathogenesis of cholestasis, N Engl J Med, 339, 1217, 10.1056/NEJM199810223391707 Trauner, 2005, Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis, J Clin Gastroenterol, 39, S111, 10.1097/01.mcg.0000155551.37266.26 Geier, 2006, Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis, Nat Clin Pract Gastroenterol Hepatol, 3, 574, 10.1038/ncpgasthep0602 Kubitz, 1999, Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone, Gastroenterology, 116, 401, 10.1016/S0016-5085(99)70138-1 Trauner, 1997, The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis, Gastroenterology, 113, 255, 10.1016/S0016-5085(97)70103-3 Zollner, 2001, Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases, Hepatology, 33, 633, 10.1053/jhep.2001.22646 Hinoshita, 2001, Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection, J Hepatol, 35, 765, 10.1016/S0168-8278(01)00216-1 Carter, 2007, Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis, Nat Clin Pract Gastroenterol Hepatol, 4, 277, 10.1038/ncpgasthep0796 Nishimura, 2005, Role of soybean oil fat emulsion in the prevention of hepatic xenobiotic transporter mRNA up- and down-regulation induced by overdose of fat-free total parenteral nutrition in infant rats, Drug Metab Pharmacokinet, 20, 46, 10.2133/dmpk.20.46 Carter, 2007, Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR, Pediatr Res, 62, 301, 10.1203/PDR.0b013e3181256492 Nishimura, 2006, Soybean oil fat emulsion to prevent TPN-induced liver damage: possible molecular mechanisms and clinical implications, Biol Pharm Bull, 29, 855, 10.1248/bpb.29.855 Mesotten, 2009, The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients, J Clin Endocrinol Metab, 94, 2345, 10.1210/jc.2008-2579 Duran-Sandoval, 2004, Glucose regulates the expression of the farnesoid X receptor in liver, Diabetes, 53, 890, 10.2337/diabetes.53.4.890 Stieger, 2000, Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver, Gastroenterology, 118, 422, 10.1016/S0016-5085(00)70224-1 Meier, 2006, Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver, Hepatology, 44, 62, 10.1002/hep.21214 Lang, 2007, Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury, Pharmacogenet Genomics, 17, 47, 10.1097/01.fpc.0000230418.28091.76 Zollner, 2007, Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis, Liver Int, 27, 920, 10.1111/j.1478-3231.2007.01506.x Boyer, 2006, Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha–OSTbeta in cholestasis in humans and rodents, Am J Physiol Gastrointest Liver Physiol, 290, G1124, 10.1152/ajpgi.00539.2005 Shoda, 2001, The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function, Am J Gastroenterol, 96, 3368, 10.1111/j.1572-0241.2001.05339.x Geier, 2007, Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration, Biochim Biophys Acta, 1773, 283, 10.1016/j.bbamcr.2006.04.014 Zollner, 2009, Nuclear receptors as therapeutic targets in cholestatic liver diseases, Br J Pharmacol, 156, 7, 10.1111/j.1476-5381.2008.00030.x Tanaka, 1992, Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor, Biochem Biophys Res Commun, 188, 942, 10.1016/0006-291X(92)91146-H Marschall, 2005, Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans, Gastroenterology, 129, 476, 10.1016/j.gastro.2005.05.009 Beuers, 2006, Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis, Nat Clin Pract Gastroenterol Hepatol, 3, 318, 10.1038/ncpgasthep0521 Paumgartner, 2002, Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited, Hepatology, 36, 525, 10.1053/jhep.2002.36088 Staudinger, 2001, The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity, Proc Natl Acad Sci USA, 98, 3369, 10.1073/pnas.051551698 Zollner, 2003, Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine, J Hepatol, 39, 480, 10.1016/S0168-8278(03)00228-9 Zollner, 2006, Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids, Am J Physiol Gastrointest Liver Physiol, 290, G923, 10.1152/ajpgi.00490.2005 Arenas, 2008, Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells, J Clin Invest, 118, 695 Medina, 1997, Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis, Hepatology, 25, 12, 10.1002/hep.510250104 Prieto, 1999, Assessment of biliary bicarbonate secretion in humans by positron emission tomography, Gastroenterology, 117, 167, 10.1016/S0016-5085(99)70564-0 Medina, 2011, Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis, Dig Dis, 29, 103, 10.1159/000324144 Salas, 2008, Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis, Gastroenterology, 134, 1482, 10.1053/j.gastro.2008.02.020 Rautiainen, 2005, Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial, Hepatology, 41, 747, 10.1002/hep.20646 Mason A, Luketic V, Lindor K, Hirschfield G, Gordon S, Mayo M, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of int-747 to ursodeoxycholic acid. EASL 2010. Available from: http://www.kenes.com/easl2010/orals/105.htm. Wagner, 2011, Nuclear receptors in liver disease, Hepatology, 53, 1023, 10.1002/hep.24148 Huang, 2003, Farnesoid X-receptor activates transcription of the phospholipid pump MDR3, J Biol Chem, 278, 51085, 10.1074/jbc.M308321200 Shoda, 2004, Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4, J Lipid Res, 45, 1813, 10.1194/jlr.M400132-JLR200 Hazzan, 2010, Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid, J Clin Gastroenterol, 44, 371, 10.1097/MCG.0b013e3181c115b3 EASL Clinical Practice Guidelines, 2009, Management of cholestatic liver diseases, J Hepatol, 51, 237, 10.1016/j.jhep.2009.04.009 Nakamuta, 2010, Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway, Int J Clin Pharmacol Ther, 48, 22, 10.5414/CPP48022 Baghdasaryan, 2011, Dual FXR/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO3− output, Hepatology, 54, 1303, 10.1002/hep.24537 Fickert, 2006, 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice, Gastroenterology, 130, 465, 10.1053/j.gastro.2005.10.018 Yoon, 1986, Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents, Gastroenterology, 90, 837, 10.1016/0016-5085(86)90859-0 Moustafa, 2012, Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury, Gastroenterology, 142, e112 Bachs, 1989, Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis, Lancet, 1, 574, 10.1016/S0140-6736(89)91608-5 Huang, 2004, A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR, J Clin Invest, 113, 137, 10.1172/JCI200418385 Wagner, 2005, CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice, Hepatology, 42, 420, 10.1002/hep.20784 Van Erpecum, 2011, Pathogenesis of cholesterol and pigment gallstones: an update, Clin Res Hepatol Gastroenterol, 35, 281, 10.1016/j.clinre.2011.01.009 Wittenburg, 2003, FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice, Gastroenterology, 125, 868, 10.1016/S0016-5085(03)01053-9 Krawczyk, 2011, Dissecting the genetic heterogeneity of gallbladder stone formation, Semin Liver Dis, 31, 157, 10.1055/s-0031-1276645 Jiang, 2008, Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients, J Lipid Res, 49, 464, 10.1194/jlr.M700295-JLR200 Uppal, 2008, Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization, Hepatology, 47, 1331, 10.1002/hep.22175 Biddinger, 2008, Hepatic insulin resistance directly promotes formation of cholesterol gallstones, Nat Med, 14, 778, 10.1038/nm1785 Henkel, 2005, Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones, Mamm Genome, 16, 903, 10.1007/s00335-004-2465-2 Lammert, 2004, Spontaneous cholecysto- and hepatolithiasis in Mdr2−/− mice. a model for low phospholipid-associated cholelithiasis, Hepatology, 39, 117, 10.1002/hep.20022 Rosmorduc, 2007, Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene, Orphanet J Rare Dis, 2, 29, 10.1186/1750-1172-2-29 Acalovschi, 2009, Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls, Lipids, 44, 521, 10.1007/s11745-009-3300-z Moschetta, 2004, Prevention of cholesterol gallstone disease by FXR agonists in a mouse model, Nat Med, 10, 1352, 10.1038/nm1138 Kovacs, 2008, Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans, J Hepatol, 48, 116, 10.1016/j.jhep.2007.07.027 Bergheim, 2006, Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers, J Lipid Res, 47, 42, 10.1194/jlr.M500215-JLR200 Renner, 2009, A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease, PLoS ONE, 4, e7321, 10.1371/journal.pone.0007321 Jung, 2004, Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor, Gut, 53, 78, 10.1136/gut.53.1.78 Wang, 2001, An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas, Cancer Epidemiol Biomarkers Prev, 10, 931 Grunhage, 2008, Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on the development of sporadic and familial colorectal cancer: a case control study, BMC Med Genet, 9, 70, 10.1186/1471-2350-9-70 Inagaki, 2006, Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor, Proc Natl Acad Sci USA, 103, 3920, 10.1073/pnas.0509592103 Gadaleta, 2011, Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease, Gut, 60, 463, 10.1136/gut.2010.212159 Modica, 2012, Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis, Gastroenterology, 142, 355, 10.1053/j.gastro.2011.10.028 Kremer, 2012, Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions, Hepatology, 56, 1391, 10.1002/hep.25748 Garg, 1994, Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial, Ann Intern Med, 121, 416, 10.7326/0003-4819-121-6-199409150-00004 Shang, 2010, Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1, Am J Physiol Gastrointest Liver Physiol, 298, G419, 10.1152/ajpgi.00362.2009 Shepherd, 1979, The effects of cholestyramine on high density lipoprotein metabolism, Atherosclerosis, 33, 433, 10.1016/0021-9150(79)90036-4 Buchwald, 1990, Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the surgical control of the hyperlipidemias (POSCH), N Engl J Med, 323, 946, 10.1056/NEJM199010043231404 Huff, 2002, Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB, Arterioscler Thromb Vasc Biol, 22, 1884, 10.1161/01.ATV.0000035390.87288.26 Bhat, 2003, Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE−/− mice by SC-435, J Lipid Res, 44, 1614, 10.1194/jlr.M200469-JLR200 Simren, 2011, Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation – a double-blind study, Aliment Pharmacol Ther, 34, 41, 10.1111/j.1365-2036.2011.04675.x Moschetta, 2003, Basolateral Ca2+-dependent K+-channels play a key role in Cl− secretion induced by taurodeoxycholate from colon mucosa, Biol Cell, 95, 115, 10.1016/S0248-4900(03)00011-X Hofmann, 2008, Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients, J Pediatr Gastroenterol Nutr, 47, 598, 10.1097/MPG.0b013e31816920a6 Rao, 2010, Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis, Gastroenterology, 139, 10.1053/j.gastro.2010.07.052 Fernandez-Banares, 2007, Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics, Am J Gastroenterol, 102, 2520, 10.1111/j.1572-0241.2007.01438.x Sinha, 1998, Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine, Aliment Pharmacol Ther, 12, 839, 10.1046/j.1365-2036.1998.00388.x Hylemon, 2009, Bile acids as regulatory molecules, J Lipid Res, 50, 1509, 10.1194/jlr.R900007-JLR200 Thomas, 2008, Targeting bile-acid signalling for metabolic diseases, Nat Rev Drug Discov, 7, 678, 10.1038/nrd2619 Figge, 2004, Hepatic over-expression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis, J Biol Chem, 279, 2790, 10.1074/jbc.M307363200 Sundaram, 2005, Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine–choline-deficient diet, Am J Physiol Gastrointest Liver Physiol, 288, G1321, 10.1152/ajpgi.00455.2004 Andreotti, 2009, Genetic determinants of serum lipid levels in Chinese subjects: a population-based study in Shanghai, China, Eur J Epidemiol, 24, 763, 10.1007/s10654-009-9402-3 Krawczyk, 2009, Body mass index in the general population is associated with the common p.A444V variant of the ABC transporter for bile salts, Hepatology, 50, 1016A Pizarro, 2004, Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function, Gut, 53, 1837, 10.1136/gut.2003.037689 Chopra, 2011, Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption, Cell Metab, 13, 35, 10.1016/j.cmet.2010.12.001 Cheng, 2008, Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity, Mol Pharm, 5, 77, 10.1021/mp700114j Fickert, 2001, Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver, Gastroenterology, 121, 170, 10.1053/gast.2001.25542 Haedrich, 2011, UDCA for NASH: end of the story?, J Hepatol, 54, 856, 10.1016/j.jhep.2010.10.009 Ozcan, 2006, Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes, Science, 313, 1137, 10.1126/science.1128294 Yang, 2010, Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice, PLoS One, 5, e13858, 10.1371/journal.pone.0013858 Ratziu, 2011, A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis, J Hepatol, 54, 1011, 10.1016/j.jhep.2010.08.030 Sanyal, 2009, A new therapy for nnonalcoholic fatty liver disease and diabetes? INT-747 – the first FXR hepatic therapeutic study, Hepatology, 50, 302A Zhang, 2009, Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis, J Hepatol, 51, 380, 10.1016/j.jhep.2009.03.025 Gupta, 2010, Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway, Hepatology, 51, 1584, 10.1002/hep.23569 Svegliati-Baroni, 2011, Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis, Liver Int, 31, 1285, 10.1111/j.1478-3231.2011.02462.x Ding, 2006, Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice, Hepatology, 43, 173, 10.1002/hep.21006 Xu, 1993, Bile secretion and liver regeneration in partially hepatectomized rats, Ann Surg, 218, 176, 10.1097/00000658-199308000-00009 Miura, 2011, Sustained repression and translocation of Ntcp and expression of Mrp4 for cholestasis after rat 90% partial hepatectomy, J Hepatol, 55, 407, 10.1016/j.jhep.2010.11.023 Gerloff, 1999, Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver, Gastroenterology, 117, 1408, 10.1016/S0016-5085(99)70291-X Vos, 1999, Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats, Hepatology, 29, 1833, 10.1002/hep.510290638 Chang, 2004, Expression of MRP2 and MRP3 during liver regeneration after 90% partial hepatectomy in rats, Transplantation, 77, 22, 10.1097/01.TP.0000089234.93366.6D Geier, 2003, Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis, Hepatology, 38, 345, 10.1053/jhep.2003.50317 Fernández-Barrena Maite, 2012, Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice, J Hepatol, 56, 367, 10.1016/j.jhep.2011.05.031 Ueda, 2002, Lack of intestinal bile results in delayed liver regeneration of normal rat liver after hepatectomy accompanied by impaired cyclin E-associated kinase activity, Surgery, 131, 564, 10.1067/msy.2002.123008 Barone, 1996, Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies, Hepatology, 23, 1159 Chen, 2010, Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats, J Pharmacol Exp Ther, 334, 164, 10.1124/jpet.110.166892 Huang, 2006, Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration, Science, 312, 233, 10.1126/science.1121435 Zhang, 2009, Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration, Mol Endocrinol, 23, 137, 10.1210/me.2008-0198 Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, et al. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine. Hepatology 2012. in press, http://dx.doi.org/10.1002/hep.25905. Milona, 2010, The normal mechanisms of pregnancy-induced liver growth are not maintained in mice lacking the bile acid sensor Fxr, Am J Physiol Gastrointest Liver Physiol, 298, G151, 10.1152/ajpgi.00336.2009 Mauad, 1994, Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis, Am J Pathol, 145, 1237 Yang, 2007, Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor, Cancer Res, 67, 863, 10.1158/0008-5472.CAN-06-1078 Wolfe, 2011, Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice, J Pharmacol Exp Ther, 338, 12, 10.1124/jpet.111.179390 Lax, 2012, Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis, Int J Cancer, 130, 2232, 10.1002/ijc.26293 Scheimann, 2007, Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma, J Pediatr, 150, 556, 10.1016/j.jpeds.2007.02.030 Keitel, 2011, The membrane-bound bile acid receptor TGR5 (GPBAR-1) is highly expressed in intrahepatic cholangiocarcinoma, Hepatology, 54, 869 Zollner, 2005, Hepatobiliary transporter expression in human hepatocellular carcinoma, Liver Int, 25, 367, 10.1111/j.1478-3231.2005.01033.x Tsuboyama, 2010, Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation, Radiology, 255, 824, 10.1148/radiol.10091557